Cerecor Inc (NASDAQ:CERC) was the target of a large decrease in short interest in January. As of January 12th, there was short interest totalling 777,488 shares, a decrease of 33.8% from the December 29th total of 1,174,319 shares. Approximately 4.1% of the company’s stock are short sold. Based on an average daily volume of 493,309 shares, the short-interest ratio is presently 1.6 days.
Shares of Cerecor (NASDAQ:CERC) opened at $3.47 on Monday. Cerecor has a 52 week low of $0.34 and a 52 week high of $4.25. The stock has a market cap of $90.41 and a P/E ratio of 9.38.
Cerecor (NASDAQ:CERC) last posted its earnings results on Monday, November 6th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.76. Cerecor had a net margin of 51.71% and a return on equity of 212.90%. analysts expect that Cerecor will post 0.83 EPS for the current year.
A hedge fund recently bought a new stake in Cerecor stock. Acadian Asset Management LLC acquired a new stake in shares of Cerecor Inc (NASDAQ:CERC) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 60,719 shares of the company’s stock, valued at approximately $194,000. Acadian Asset Management LLC owned approximately 0.23% of Cerecor as of its most recent filing with the SEC. 64.03% of the stock is owned by institutional investors.
CERC has been the topic of several recent analyst reports. ValuEngine upgraded shares of Cerecor from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 7th. TheStreet upgraded shares of Cerecor from an “e+” rating to a “c-” rating in a research note on Wednesday, November 8th.
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.